Zydus Cadila gets USFDA nod for depression drug Vortioxetine

Published On 2021-09-19 05:30 GMT   |   Update On 2021-09-19 05:30 GMT
Advertisement

Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Vortioxetine Tablets in the strengths of 5 mg, 10 mg, 20 mg (US RLD: Trintellix Tablets).

Vortioxetine is used to treat depression. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain.

Advertisement

Vortioxetine is an SSRI (selective serotonin reuptake inhibitor) and serotonin receptor modulator.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 322 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

USFDA had approved another depression drug earlier this year manufactured by Zydus Cadila.

Medical Dialogues team had earlier reported that the company had received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).

This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, and increase one's energy level.

Read also: Zydus Cadila secures USFDA nod for Nortriptyline Hydrochloride Capsules

Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.

The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News